Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Uniphar in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 225.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Uniphar. This N/A consensus rating has held steady for over two years.
Uniphar plc operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, and internationally. The company operates through three divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division offers outsourced sales, marketing, and multichannel account management services to pharmaco-medical manufacturers; and distribution and support services to medical device manufacturers. The Product Access division provides on demand services, which offers access to pharmaco-medical products and treatments by developing valuable relationships and interactions between manufacturers and other healthcare stakeholders; and exclusive access services that provides bespoke distribution partnerships to pharmaceutical partners for key brands. The Supply Chain & Retail division engages in pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons; and operates a network of pharmacies under the Life, Allcare, and Hickey's brands. It also offers pharmacy support, pharmaceutical supply chain, specialist nursing and infusion, medical device distribution, healthcare technology, data intelligence and consultancy services, pharmaceutical advisory, medical affairs, and online pharmacy and product fostering services, as well as data solutions for pharma industry. Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.
Read More